Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, approved for the treatment of type 2 diabetes and obesity. It mimics the natural hormone GLP-1, which plays a crucial role in regulating blood sugar levels and promoting satiety.

As a GLP-1 receptor agonist, Semaglutide helps to improve blood sugar control by stimulating the release of insulin and reducing glucagon production. Additionally, its ability to increase feelings of fullness and reduce appetite can aid in weight loss or weight maintenance. Studies have also demonstrated that Semaglutide can lower the risk of cardiovascular events in individuals with type 2 diabetes.

With its demonstrated efficacy in managing type 2 diabetes and obesity, Semaglutide represents a promising treatment option for individuals seeking to improve their overall health and well-being.

H-H-Aib-EGTFTSDVSSYLEGQAAK(((AEEA)2-gamma-Glu-17-carboxyheptadecanoyl)-EFIAWLVRGRG-OH

H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys((AEEA)2-gamma-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH